OBJECTIVE: Major depressive disorder (MDD) is associated with immune system dysfunction and disruption of multiple circadian systems. Adiponectin is an adipocytokine with anti-inflammatory and antiatherogenic effects. Circulating concentrations are inversely related to adiposity and risks of metabolic syndrome and diabetes mellitus. Our goals were (1) to establish whether premenopausal women with MDD exhibit decreased plasma adiponectin concentrations and/or disruption of circadian adiponectin rhythmicity; (2) to assess whether there is a relationship between adiponectin and MDD; and (3) to explore the temporal relationships among adiponectin, leptin, corticotropin, and cortisol secretion. METHOD: We conducted a case-control study of community-dwelling premenopausal women with DSM-IV MDD (n = 23) and age- and body mass index (BMI)-matched control subjects (n = 23). Main outcome measures were circulating concentrations of adiponectin, leptin, corticotropin, and cortisol measured hourly for 24 hours. Subjects were recruited from July 1, 2001, to February 28, 2003. RESULTS: Women with MDD had approximately 30% lower mean 24-hour concentration of adiponectin than did control subjects. Adiponectin concentration was inversely related to depression severity and total duration of disease, suggesting a causal link. In contrast, mean nocturnal leptin concentration was higher in the MDD versus control groups. Mean leptin concentration was inversely related to cortisol and adiponectin concentrations, both in subjects with depression and in control subjects. In cross-correlation analyses, the relationship between corticotropin and cortisol concentrations was stronger in women with MDD than in control subjects, a finding consistent with hypothalamic-pituitary-adrenal (HPA) axis activation in MDD. CONCLUSIONS: In premenopausal women with MDD, reduced daily adiponectin production may increase the risk of diabetes mellitus, and elevated leptin may contribute to osteoporosis. Copyright 2010 Physicians Postgraduate Press, Inc.
OBJECTIVE:Major depressive disorder (MDD) is associated with immune system dysfunction and disruption of multiple circadian systems. Adiponectin is an adipocytokine with anti-inflammatory and antiatherogenic effects. Circulating concentrations are inversely related to adiposity and risks of metabolic syndrome and diabetes mellitus. Our goals were (1) to establish whether premenopausal women with MDD exhibit decreased plasma adiponectin concentrations and/or disruption of circadian adiponectin rhythmicity; (2) to assess whether there is a relationship between adiponectin and MDD; and (3) to explore the temporal relationships among adiponectin, leptin, corticotropin, and cortisol secretion. METHOD: We conducted a case-control study of community-dwelling premenopausal women with DSM-IV MDD (n = 23) and age- and body mass index (BMI)-matched control subjects (n = 23). Main outcome measures were circulating concentrations of adiponectin, leptin, corticotropin, and cortisol measured hourly for 24 hours. Subjects were recruited from July 1, 2001, to February 28, 2003. RESULTS:Women with MDD had approximately 30% lower mean 24-hour concentration of adiponectin than did control subjects. Adiponectin concentration was inversely related to depression severity and total duration of disease, suggesting a causal link. In contrast, mean nocturnal leptin concentration was higher in the MDD versus control groups. Mean leptin concentration was inversely related to cortisol and adiponectin concentrations, both in subjects with depression and in control subjects. In cross-correlation analyses, the relationship between corticotropin and cortisol concentrations was stronger in women with MDD than in control subjects, a finding consistent with hypothalamic-pituitary-adrenal (HPA) axis activation in MDD. CONCLUSIONS: In premenopausal women with MDD, reduced daily adiponectin production may increase the risk of diabetes mellitus, and elevated leptin may contribute to osteoporosis. Copyright 2010 Physicians Postgraduate Press, Inc.
Authors: Bulent O Yildiz; Marc A Suchard; Ma-Li Wong; Samuel M McCann; Julio Licinio Journal: Proc Natl Acad Sci U S A Date: 2004-07-01 Impact factor: 11.205
Authors: Robert S Lindsay; Tohru Funahashi; Robert L Hanson; Yuji Matsuzawa; Sachiyo Tanaka; P Antonio Tataranni; William C Knowler; Jonathan Krakoff Journal: Lancet Date: 2002-07-06 Impact factor: 79.321
Authors: Menotti Calvani; Antonio Scarfone; Luigi Granato; Elena Valera Mora; Giuseppe Nanni; Marco Castagneto; Aldo V Greco; Melania Manco; Geltrude Mingrone Journal: Diabetes Date: 2004-04 Impact factor: 9.461
Authors: J Fruebis; T S Tsao; S Javorschi; D Ebbets-Reed; M R Erickson; F T Yen; B E Bihain; H F Lodish Journal: Proc Natl Acad Sci U S A Date: 2001-02-06 Impact factor: 11.205
Authors: Alina Gavrila; C-K Peng; Jean L Chan; Joseph E Mietus; Ary L Goldberger; Christos S Mantzoros Journal: J Clin Endocrinol Metab Date: 2003-06 Impact factor: 5.958
Authors: Janice K Kiecolt-Glaser; Lisa M Christian; Rebecca Andridge; Beom Seuk Hwang; William B Malarkey; Martha A Belury; Charles F Emery; Ronald Glaser Journal: Physiol Behav Date: 2012-01-27
Authors: Jing Liu; Ming Guo; Di Zhang; Shao-Ying Cheng; Meilian Liu; Jun Ding; Philipp E Scherer; Feng Liu; Xin-Yun Lu Journal: Proc Natl Acad Sci U S A Date: 2012-07-09 Impact factor: 11.205
Authors: Susan A Everson-Rose; Cari J Clark; Qi Wang; Hongfei Guo; Peter Mancuso; Howard M Kravitz; Joyce T Bromberger Journal: Psychoneuroendocrinology Date: 2018-07-05 Impact factor: 4.905
Authors: R Machado-Vieira; P W Gold; D A Luckenbaugh; E D Ballard; E M Richards; I D Henter; R T De Sousa; M J Niciu; P Yuan; C A Zarate Journal: Mol Psychiatry Date: 2016-04-05 Impact factor: 15.992
Authors: Faisal Akram; Claudia Gragnoli; Uttam K Raheja; Soren Snitker; Christopher A Lowry; Kelly A Stearns-Yoder; Andrew J Hoisington; Lisa A Brenner; Erika Saunders; John W Stiller; Kathleen A Ryan; Kelly J Rohan; Braxton D Mitchell; Teodor T Postolache Journal: J Psychiatr Res Date: 2020-01-02 Impact factor: 4.791